Cerevel Therapeutics Holdings Inc (CERE)
42.10
-0.25
(-0.59%)
USD |
NASDAQ |
May 17, 16:00
42.10
0.00 (0.00%)
Pre-Market: 20:00
Cerevel Therapeutics Holdings Cash from Investing (Quarterly): 19.16M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 19.16M |
| December 31, 2023 | -150.21M |
| September 30, 2023 | 51.39M |
| June 30, 2023 | 61.75M |
| March 31, 2023 | 110.78M |
| December 31, 2022 | -26.73M |
| September 30, 2022 | -387.85M |
| June 30, 2022 | 64.29M |
| March 31, 2022 | -38.54M |
| Date | Value |
|---|---|
| December 31, 2021 | -426.23M |
| September 30, 2021 | -1.188M |
| June 30, 2021 | -3.583M |
| March 31, 2021 | -4.66M |
| December 31, 2020 | -7.551M |
| September 30, 2020 | -7.299M |
| June 30, 2020 | -1.486M |
| March 31, 2020 | -2.556M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-426.23M
Minimum
Dec 2021
110.78M
Maximum
Mar 2023
-44.15M
Average
-3.583M
Median
Jun 2021
Cash from Investing (Quarterly) Benchmarks
| AbbVie Inc | -9.588B |
| Bristol-Myers Squibb Co | -19.62B |
| Madrigal Pharmaceuticals Inc | 98.05M |
| Viking Therapeutics Inc | -459.79M |
| Karuna Therapeutics Inc (DELISTED) | 92.44M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -119.67M |
| Cash from Financing (Quarterly) | 4.475M |
| Free Cash Flow | -370.79M |
| Free Cash Flow Per Share (Quarterly) | -0.6604 |
| Free Cash Flow Yield | -5.23% |